BED EIA HIV-1 Incidence Test (Calypte Biomedical Corporation, Portland, Oregon) indicated recent HIV infection. HLA typing using sequence-specific oligonucleotide-primed PCR and Luminex technology identified HLA-A*01, HLA-A*03, HLA-B*27, and HLA-B*35: all not associated with rapid development of HIV-related immunodeficiency; in contrast, HLA-B*27 is associated with slow disease progression. Antiretroviral therapy (ART) with tenofovir/emtricitabine and raltegravir was initiated. After 21 days of treatment, the patient was discharged on prophylactic doses of TMP/SMX. Chest radiographs were nearly normal, the HIV-1 viral load drastically declined (427 copies/ml), the CD4 count rose to 250 cells/mm³, and cytokine concentrations normalized. After 25 days, the patient was readmitted with progressive dyspnea, dry cough, chest pain, headache, subfebrile temperatures, and persistent rash. Clinically, she was tachypneic (40/min), tachycardic (128/min), and subfebrile (37.3 °C); a rash was hardly noticeable, and on auscultation expiratory wheezes on the right side and prolonged expirium were heard. Except for elevated C-reactive protein (84 mg/l), blood tests were unremarkable. The HIV-1 viral load further declined to 188 copies/ml and the CD4 T cell count was 356 cells/mm³ (13%). Chest radiographs showed a consolidation above the right hilum. Oxygen therapy and TMP/SMX with corticosteroids was restarted. Bronchoalveolar lavage was negative for P. jirovecii, Legionella pneumophila, Mycobacterium tuberculosis, and other pathogenic bacteria and fungi. At that time, diagnosis of lower respiratory system infection in the setting of PCP-related immune reconstitution inflammatory syndrome (PCP-IRIS) was most probable due to negative microbiological tests and rapid restoration of immunity. After 2 weeks of therapy, the intensity of consolidation regressed and the patient was discharged on prophylactic doses of TMP/SMX and ART. Twenty days after bronchoscopy, bronchoalveolar lavage was positive (40 colonies) for Mycobacterium avium complex (MAC). The patient successfully recovered after 14 months of MAC-IRIS treatment with clarithromycin and ethambutol with CD4 counts of 324 cells/mm³ and a viral load of < 40 copies/ml.
Discussion
The suspicion that our patient's condition was a rapidly progressing HIV infection and not a primary HIV infection was supported by several facts: (i) the flu-like illness after traveling to the Philippines was probably primary HIV infection; (ii) the patient is infected with HIV-1 subtype A1, which is rarely found in Slovenia (1); and (iii) a high HIV-1 viral load and low CD4 T cells with rapid virological/immunological improvement after ART initiation. After primary HIV infection of mild intensity, profound immunosuppression occurred, leading to greater susceptibility to P. jirovecii infection-which is a characteristic pathogen in the late stages of AIDS and is only rarely seen in the early phase of HIV infection.
There is no consensus on optimal timing for initiation of ART in patients with acute opportunistic infection (2) . In patients with PCP, growing evidence supports starting ART early rather than waiting for completion of PCP treatment. A randomized controlled trial compared early versus delayed ART in 282 HIV-infected patients diagnosed with opportunistic infection, of whom 63% had PCP (3). Early ART was associated with a significant decrease in AIDS progression and death without an increase in IRIS (3).
Initially we believed that a second episode of acute lower respiratory infection was related to the rare clinical entity PCP-IRIS due to rapid immunological restoration and a drop in HIV RNA after 6 weeks of ART. Subsequently, we unexpectedly isolated MAC from bronchoalveolar lavage but, because of the patient's improvement, MAC treatment was not initiated until repeated bronchoscopy showed a positive histology and culture. During the ART era, MAC infection has developed into a completely new disease. Previously, it had occurred as a disseminated disease in patients with massive immunodeficiency (4), but under ART it is mostly localized and related to IRIS that most often occurs within 3 months of initiating treatment (5), as in our patient; it is an unmasking of subclinical disease. MAC-IRIS can present with very diverse signs and symptoms: most often lymph nodes, the liver, or the gastrointestinal tract are involved, but essentially any organ could be involved, including the lungs (6) .
HIV infection in our patient progressed very rapidly with two different opportunistic infections: PCP and, surprisingly, MAC-IRIS. Rapid progression of HIV infection into AIDS is linked to certain human as well as viral characteristics/markers. Interestingly, not a single HLA gene previously linked with rapid HIV progression (7) was identified in our patient. In contrast, a high HIV-1 viral load that does not fall dramatically after primary HIV infection, which is a strong marker of rapid HIV progression (8) , was observed in our patient. The literature suggests that some rapid progressors are infected with rapidly replicating HIV strains and have viral population with higher heterogeneity than HIV viral controllers (8) (9) (10) . Unfortunately, we were not in a position to measure these parameters in our patient. Although our patient experienced an unusual and challenging 1st year of her HIV-1 infection, she is currently doing well: after a favorable response to standard anti-MAC treatment, she is asymptomatic with normal chest radiographs, an unmeasurable HIV-1 viral load, and 318 CD4 T cells/mm³.
